Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus

IDrugs

Volumn 13, Issue 11, 2010, Pages 793-801

  Lecka Czernik, Beata ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALEGLITAZAR; ATORVASTATIN; C REACTIVE PROTEIN; CHOLINE FENOFIBRATE; FARGLITAZAR; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IBUPROFEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; RO 0728804; ROSIGLITAZONE; ROSUVASTATIN; TESAGLITAZAR; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ERYTHROCYTE COUNT; FATIGUE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; KIDNEY FUNCTION; LEUKOCYTE COUNT; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATENT; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RECEPTOR AFFINITY; RISK REDUCTION; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; WEIGHT GAIN;

ANIMALS; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; OXAZOLES; PPAR ALPHA; PPAR GAMMA; THIOPHENES;

EID: 78650262971     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. 104619 Successful management of CMV pneumonia in a mechanically ventilated patient. Sommer SE, Emanuel D, Groeger JS, Carlon GC Chest 1991 100 3 856-858
2. 327686 SB/Bristol Avandia lipid adverse effect diminishes over two months Label. FDC REP PINK SHEET 1999 61 23 20
3. 338000 Lilly and Takeda to expand Actos relationship; new agreement will provide support for Actos in additional markets. Eli Lilly & Co Press Release 1999 August 25
4. 420811 Peroxisome proliferator-activated receptor γ and metabolic disease. Willson TM, Lambert MH, Kliewer SA ANNU REV BIOCHEM 2001 70 341-367
5. 550982 Divergent effects of selective peroxisome proliferatoractivated receptor-γ 2 ligands on adipocyte versus osteoblast differentiation. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL ENDOCRINOLOGY 2002 143 6 2376-2384
6. 579216 Therapeutic significance of peroxisome proliferatoractivated receptor modulators in diabetes. Ram VJ DRUGS TODAY 2003 39 8 609-632
7. 630997 Bristol-Myers Squibb statement on muraglitazar, an investigational oral treatment for type 2 diabetes. Bristol-Myers Squibb Co PRESS RELEASE 2005 October 27
8. 665830 AstraZeneca discontinues development of Galida (tesaglitazar). AstraZeneca plc PRESS RELEASE 2006 May 04
9. 729047 Thiazolidinedione use and bone loss in older diabetic adults. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, Park SW et al J CLIN ENDOCRINOL METAB 2006 91 9 3349-3354
10. 756003 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill M C, Zinman B, Viberti G N ENGL J MED 2006 355 23 2427-2443
11. 799234 Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. Nissen SE, Wolski K N ENGL J MED 2007 356 24 2457-2471
12. 819104 NCT00388518: A study of R1439 in patients with type 2 diabetes. Hoffmann-La Roche clinicaltrials.gov 2007
13. 826754 Rodent carcinogenicity profile of the antidiabetic dual PPARα and γ agonist muraglitazar. Tannehill-Gregg SH, Sanderson TP, Minnema D, Voelker R, Ulland B, Cohen SM, Arnold LL, Schilling BE, Waites CR, Dominick MA TOXICOL SCI 2007 98 1 258-270
14. 826783 Tesaglitazar, a PPARα/γ agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcornas in subcutaneous tissues in rats. Hellmold H, Zhang H, Andersson U, Blomgren B, Holland T, Berg AL, Elebring M, Sjogren N, Bamberg K, Dahl B, Westerberg R et al TOXICOL SCI 2007 98 1 63-74
15. 842283 Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus - A meta-analysis of randomized trials. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE JAMA-J AM MED ASSOC 2007 298 10 1180-1188
16. 975293 Long-term use of thiazolidinediones and fractures in type 2 diabetes: A meta-analysis. Loke YK, Singh S, Furberg CD CMAJ 2009 180 1 32-39
17. 986398 Aleglitazar, a potent and balanced dual PPAR α/γ agonist for the treatment of type II diabetes and dyslipidemia. Mohr P, Benardeau A, Benz J, Binggeli A, Bittner B, Boehringer MP, Costanzo A, Grether UM, Hilpert H, Hirth G, Isel H et al AM CHEM SOC NATL MEET EXPOSITION 2009 237 March 22 Medi-011
18. 1001742 China 2009 Pharmaceutical R&D summit Fourth international IBC summit, Shanghai, China. Ju D IDDB MEETING REPORT 2009 April 7-9
19. 1003790 Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes. Benardeau A, Benz J, Binggeli A, Blum D, Boehringer M, Grether U, Hilpert H, Kuhn B, Marki HP, Meyer M, Puntener K et al BIOORG MED CHEM LETT 2009 19 9 2468-2473
20. 1013472 Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, provides beneficial effects on glycemic control and lipids in patients with type 2 diabetes. Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M DIABETES 2009 58 Abs 917-P
21. 1016873 Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): A phase II, randomised, dose-ranging study in patients with type 2 diabetes. Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M LANCET 2009 374 9684 126-135
22. 1027961 Roche Pharmaceuticals pipeline. F Hoffmann-La Roche Ltd COMPANY WORLD WIDE WEB SITE 2009 July 23
23. 1043653 Bone as a target of type 2 diabetes treatment. Lecka-Czernik B CURR OPIN INVESTIG DRUGS 2009 10 10 1085-1090
24. 1046913 Favorable glycemic, lipid, and safety profile of aleglitazar, a peroxisome proliferator-activated receptor (PPAR)α/γ co-agonist in patients with type 2 diabetes. D'Ardhuy XL, Banken L, Jamois C DIABETES 2009 58 Abs 924-P
25. 1046914 Aleglitazar, a balanced dual PPAR α/γ activator, exerts potent insulin-sensitizing and glucose-lowering effects in a nonhuman primate model of metabolic syndrome and type 2 diabetes mellitus. Hansen BC, Tigno XT, Benardeau A, Meyer M, Sebokova E, Mizrahi J DIABETOLOGIA 2009 52 Abs 867
26. 1046917 Glycemic and lipid effects and cardiovascular safety of a novel dual peroxisome proliferator-activated receptor α/γ agonist. Lincoff AM, Henry RR, Mudaliar S, Chognot C, Rabbia M, Herz M J AM COLL CARDIOL 2009 53 10 Abs 1021-82
27. 1046918 Comparative transcriptional network modeling of three PPAR α/γ co-agonist treatments reveals unique metabolic signatures despite similar core PPAR signaling. Blander G, Maerz-Weiss P, Catlett N, Steiner G, Wong B, Wright M, Laifenfeld D, Matthews A, Bobadilla M, Mizrahi J, Haefliger C et al DIABETES 2009 58 Abs 1121-P
28. 1053023 Chong Kun Dang to initiate a phase III clinical trial for CKD-501 for the treatment of type II diabetes. PHARMA KOREANA 2009 19 10 32-33
29. 1053730 Aleglitazar, a balanced peroxisome proliferator-activated receptor (PPAR)α/γ agonist, provides beneficial effects on cardiovascular markers of inflammation and clotting. Henry RR, Lincoff AM, Mudaliar S, Chognot C, Rabbia M, Herz M CIRCULATION 2009 120 18 Abs 849- P
30. 1054395 Aleglitazar, a balanced PPAR α/γ agonist, has no clinically relevant pharmacokinetic interaction with highdose atorvastatin or rosuvastatin. Foley-Comer A, White AM, Russell-Yarde F, Jordan P DIABETES 2009 120 18 Abs 872-P
31. 1054544 Aleglitazar, a balanced peroxisome proliferatoractivated receptor (PPAR)α/γ agonist, exerts potent lipid-modifying effects in a primate model of metabolic syndrome and type 2 diabetes. Hansen BC, Tigno XT, Benardeau A, Meyer M, Sebokova E, Mizrathi J CIRCULATION 2009 120 18 Abs 1278-OR
32. 1083167 Roche uniquely positioned to deliver long-term growth. Roche Holding AG Press Release 2010 March 18
33. 1097305 Summary of consolidated financial results for the year ended March 31, 2010 (Unaudited). Dainippon Sumitomo Pharma Co Ltd PRESS RELEASE 2010 May 10
34. 1101046 Scaffold based discovery of indeglitazar, a pan PPAR treatment for metabolic diseases. Lin J NATL MED CHEM SYMP 2010 32 June 09 Abs O7.1
35. 1120925 Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: Results from a randomized, placebo-controlled clinical study. Sanwald-Ducray P, D'Ardhuy XL, Jamois C, Banken L CLIN PHARMACOL THER 2010 88 2 197-203
36. 1129585 Oral antihyperglycemic therapy for type 2 diabetes mellitus. Cheng AYY, Fantus IG CMAJ 2005 172 2 213-226
37. 1129591 Fat and beyond: The diverse biology of PPARγ. Tontonoz P, Spiegelman BM ANNU REV BIOCHEM 2008 77 289-312
38. 1129615 Pioglitazone versus rosiglitazone: Effects on lipids, lipoproteins, and apolipoproteins in head-to-head randomized clinical studies. Deeg MA, Tan MH PPAR RES 2008 2008 520465
39. 1129645 Drug therapy: Thiazolidinediones. Yki-Jarvinen H N ENGL J MED 2004 351 11 1106-1118
40. 1129650 Sorting out the roles of PPAR α in energy metabolism and vascular homeostasis. Lefebvre P, Chinetti G, Fruchart JC, Staels B J CLIN INVEST 2006 116 3 571-580
41. 1129656 Fibrate therapy: An update. Remick J, Weintraub H, Setton R, Offenbacher J, Fisher E, Schwartzbard A CARDIOL REV 2008 16 3 129-141
42. 1129666 A cohort study of thiazolidinediones and fractures in older adults with diabetes. Solomon DH, Cadarette SM, Choudhry NK, Canning C, Levin R, Sturmer T J CLIN ENDOCRINOL METAB 2009 94 8 2792-2798
43. 1129670 Thiazolidinediones and fractures in men and women. Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM ARCH INTERN MED 2009 169 15 1395-1402
44. 1129710 Avandia outcome may signal change in epidemiologists' sway. Wadman M NAT MED 2010 16 6 614-614
45. 1129746 Safety issues and prospects for future generations of PPAR modulators. Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B BIOCHIM BIOPHYS ACTA MOL CELL BIOL LIPIDS 2007 1771 8 1065-1081
46. 1129748 Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. Habib ZA, Havstad SL, Wells K, Divine G, Pladevall M, Williams LK J CLIN ENDOCRINOL METAB 2010 95 2 592-600
47. 1129750 Use of thiazolidinediones and fracture risk. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR ARCH INTERN MED 2008 168 8 820-825
48. 1129751 Rosiglitazone-associated fractures in type 2 diabetes: An Analysis from a Diabetes Outcome Progression Trial (ADOPT). Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu DH, Heise MA, Aftring RP, Viberti G DIABETES CARE 2008 31 5 845-851
49. 1129752 Distal upper and lower limb fractures associated with thiazolidinedione use. Jones SG, Momin SR, Good MW, Shea TK, Patric K AM J MANAG CARE 2009 15 8 491-496
50. 1129755 The risk of fractures associated with thiazolidinediones: A self-controlled case-series study. Douglas IJ, Evans SJ, Pocock S, Smeeth L PLOS MED (ONLINE) 2009 6 9 e1000154
51. 1129757 Bone loss in diabetes: Use of anti-diabetic thiazolidinediones and secondary osteoporosis. Lecka-Czernik B CURR OSTEOPOROS REP 2010 8 4 178-184
52. 1129891 PPAR α: An emerging therapeutic target in diabetic microvascular damage. Hiukka A, Maranghi M, Matikainen N, Taskinen MR NAT REV ENDOCRINOL 2010 6 8 454-463
53. 1130848 Thiazolidinediones and bone. Falchetti A, Masi L, Brandia ML CLIN CASES MINER BONE METAB 2007 4 2 103-107
54. 1133286 Structure-based design of indole propionic acids as novel PPAR α/γ co-agonists. Kuhn B, Hilpert H, Benz J, Binggeli A, Grether U, Humm R, Marki HP, Meyer M, Mohr P BIOORG MED CHEM LETT 2006 16 15 4016-4020
55. 1133295 Studies on azole compounds. Goto Y, Yamazaki M, Hamana M CHEM PHARM BULL 1971 19 2050-2057
56. 1135694 Effects of high dose aleglitazar on renal function in patients with type 2 diabetes. Herz M, Gaspari F, Perico N, Viberti G, Urbanowska T, Rabbia M, Kirk DW INT J CARDIOL 2010 Epub ahead of print